Inflammation-activated protein kinases as targets for drug development

Proceedings of the American Thoracic Society

Volumn 2, Issue 4, 2005, Pages 386-390

  Karin, Michael ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiinflammatory drugs; Extracellular signal regulated kinase; I B kinase; jun N terminal kinase; p38 mitogen activated protein kinase

Indexed keywords

ANTIINFLAMMATORY AGENT; CYTOKINE; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; CELL SURVIVAL; CELL TYPE; CONFERENCE PAPER; DRUG TARGETING; GENE EXPRESSION; INFLAMMATION; INNATE IMMUNITY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; I-KAPPA B KINASE; INFLAMMATION; MAP KINASE KINASE 4; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; TRANS-ACTIVATION (GENETICS);

EID: 28244488706     PISSN: 15463222     EISSN: 15463222     Source Type: Journal    
DOI: 10.1513/pats.200504-034SR     Document Type: Conference Paper

References (51)

1. Barnes PJ, Karin M. NF-κB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-1071.
2. Li Q, Verma IM. NF-κB regulation in the immune system. Nat Rev Immunol 2002;2:725-734.
3. Ghosh S, Karin M. Missing pieces in the NF-κB puzzle. Cell 2002;109:S81-S96.
4. Bonizzi G, Karin M. The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004;25:280-288.
5. Senftleben U, Cao Y, Xiao G, Greten FR, Krähn G, Bonizzi G, Chen Y, Hu Y, Fong A, Sun SC, et al. Activation by IKKa of a second, evolutionary conserved, NF-κB signaling pathway. Science 2001;293:1495-1499.
6. Chen LW, Egan L, Li ZW, Greten FR, Kagnoff MF, Karin M. The two faces of IKK and NF-κB inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion. Nat Med 2003;9:575-581.
7. Thanos D, Maniatis T. Virus induction of human IFNβ gene expression requires the assembly of an enhanceosome. Cell 1995;83:1091-1100.
8. Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem 1995;270:16483-16486.
9. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001;410:37-40.
10. Zhang L, Wang W, Hayashi Y, Jester JV, Birk DE, Gao M, Liu CY, Kao WW, Karin M, Xia Y. A role for MEK kinase 1 in TGF-β/activin-induced epithelium movement and embryonic eyelid closure. EMBO J 2003;22:4443-4454.
11. Baud V, Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol 2001;11:372-377.
12. Mak TW, Yeh WC. Signaling for survival and apoptosis in the immune system. Arthritis Res 2002;4:S243-S252.
13. Wallach D, Arumugam TU, Boldin MP, Cantarella G, Ganesh KA, Goltsev Y, Goncharov TM, Kovalenko AV, Rajput A, Varfolomeev EE, et al. How are the regulators regulated? The search for mechanisms that impose specificity on induction of cell death and NF-κB activation by members of the TNF/NGF receptor family. Arthritis Res 2002;4:S189-S196.
14. Tada K, Okazaki T, Sakon S, Kobarai T, Kurosawa K, Yamaoka S, Hashimoto K, Mak TW, Yagita H, Okumura K, et al. Critical roles of TRAF2 and TRAF5 in tumor necrosis factor-induced NF-κB activation and protection from cell death. J Biol Chem 2001;276:36530-36534.
15. Lomaga MA, Yeh WC, Sarosi I, Duncan GS, Furlonger C, Ho A, Morony S, Capparelli C, Van G, Kaufman S, et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev 1999;13:1015-1024.
16. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001;1:135-145.
17. Rothwarf DM, Karin M. The NF-κB activation pathway: a paradigm in information transfer from membrane to nucleus. Sci STKE 1999;5:RE1
18. Li Q, Van Antwerp D, Mercurio F, Lee KF, Verma IM. Severe liver degeneration in mice lacking the IκB kinase 2 gene. Science 1999;284:321-325.
19. Li ZW, Chu W, Hu Y, Delhase M, Deerinck T, Ellisman M, Johnson R, Karin M. The IKKβ subunit of IκB kinase (IKK) is essential for nuclear factor κB activation and prevention of apoptosis. J Exp Med 1999;189:1839-1845.
20. Hsu LC, Park JM, Zhang K, Luo JL, Maeda S, Kaufman RJ, Eckman L, Guiney DG, Marin M. The protein kinase PKR is required for macrophage apoptosis after activation of Toll-like receptor 4. Nature 2004;428:341-345.
21. Hu Y, Baud V, Delhase M, Zhang P, Deerinck T, Ellisman M, Johnson R, Karin M. Abnormal morphogenesis but intact IKK activation in mice lacking the IKKα subunit of the IκB kinase. Science 1999;284:316-320.
22. Egan LJ, Eckman L, Greten FR, Chae S, Li ZW, Myhre GM, Robine S, Karin M, Kagnoff MF. IκB-dependent NF-κB activation provides radioprotection to the intestinal epithelium. Proc Natl Acad Sci USA 2004;101:2452-2457.
23. Greten FR, Eckman L, Greten TF, Park JO, Li ZW, Egan LJ, Kagnoff MF, Karin M. IKKβ links inflammation and tumorgenesis in a mouse model of colitis associated cancer. Cell 2004;118:285-296.
24. Maeda S, Hsu LC, Liu H, Bankston LA, Iimura M, Kagnoff MF, Eckmann L, Karin M. Nod2 mutation in Crohn's disease potentiates NF-κB activity and IL-1β processing. Science 2005;307:734-738.
25. Ruocco MG, Maeda S, Park JM, Lawrence T, Hsu LC, Cao Y, Schett G, Wagner EF, Karin M. IκB kinase (IKK)β, but not IKKα, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J Exp Med 2005;201:1677-1687.
26. Jimi E, Aoki K, Saito H, D'Acquisto F, May MJ, Nakamura I, Sudo T, Kojima T, Okamoto F, Fukushima H, et al. Selective inhibition of NF-κB blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med 2004;10:617-624.
27. Karin M, Lin A. NF-κB at the crossroads of life and death. Nat Immunol 2002;3:221-227.
28. Karin M, Yamamoto Y, Wang QM. The IKK NF-κB system: a treasure trove for drug development. Nat Rev Drug Discov 2004;3:17-26.
29. Dumitru CD, Ceci JD, Tsatsanis C, Kontoyiannis D, Stamatakis K, Lin J-H, Patriotis C, Jenkins NA, Copeland NG, Kollias G, et al. TNF-α induction by LPS is regulated posttranscriptionally via a Tp12/ERK-dependent pathway. Cell 2000;103:1071-1083.
30. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 1995;92:7686-7689.
31. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F, et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 1998;273:18623-18632.
32. Waterfield M, Jin W, Reiley W, Zhang M, Sun SC. IκB kinase is an essential component of the Tp12 signaling pathway. Mol Cell Biol 2004;24:6040-6048.
33. McIntyre KW, Shuster DJ, Gillooly KM, Dambach DM, Pattoli MA, Lu P, Zhou XD, Qiu Y, Zusi FC, Burke JR. A highly selective inhibitor of IκB kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice. Arthritis Rheum 2003;48:2652-2659.
34. Han Z, Boyle DL, Chang L, Bermett B, Karin M, Yang L, Manning AM, Firestein GS. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest 2001;108:73-81.
35. Hibi M, Lin A, Smeal T, Minden A, Karin M. Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev 1993;7:2135-2148.
36. Gupta S, Campbell D, Dérijard B, Davis RJ. Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science 1995;267:389-393.
37. Cavigelli M, Li WW, Lin A, Su B, Yoshioka K, Karin M. The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase. EMBO J 1996;15:6269-6279.
38. Chang L, Jones Y, Ellisman MH, Goldstein LS, Karin M. JNK1 is required for maintenance of neuronal niicrotubules and controls phosphorylation of microtubule-associated proteins. Dev Cell 2003;4:521-533.
39. Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1991;1072:129-157.
40. Brenner DA, O'Hara M, Angel P, Chojkier M, Karin M. Prolonged activation of jun and collagenase genes by tumour necrosis factor-α. Nature 1989;337:661-663.
41. Hirosumi J, Tuncman G, Chang L, Görgün CZ, Uysal KT, Maeda K, Karin M, Hotamisligil GS. A central role for JNK in obesity and insulin resistance. Nature 2002;420:333-336.
42. Tang G, Minemoto Y, Dibling B, Purcell NH, Li Z, Karin M, Lin A. Inhibition of JNK activation through NF-κB target genes. Nature 2001;414:313-317.
43. Maeda S, Chang L, Li ZW, Luo JL, Leffert H, Karin M. IKKβ is required for prevention of apoptosis mediated by cell-bound but not by circulating TNFα. Immunity 2003;19:725-737.
44. Freshney NW, Rawlinson L, Guesdon F, Jones E, Cowley S, Hsuan J, Saklatvala J. Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of HSP27. Cell 1994;78:1039-1049.
45. Han J, Lee JD, Bibbs L, Ulevitch RJA. MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 1994;265:808-811.
46. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR, Landvatter SW, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994;372:739-746.
47. Nishikawa M, Myoui A, Tomita T, Takahi K, Nampei A, Yoshikawa H. Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR167653. Arthritis Rheum 2003;48:2670-2681.
48. Park JM, Greten FR, Li ZW, Karin M. Macrophage apoptosis by anthrax lethal factor and p38 MAP kinase inhibition. Science 2002;297:2048-2051.
49. Cerretti DP, Kozlosky CJ, Mosley B, Nelson N, Van Ness K, Greenstreet TA, March CJ, Kronheim SR, Druck T, Cannizzaro LA, et al. Molecular cloning of the interleukin-1β converting enzyme. Science 1992;256:97-100.
50. Thornberry NA, Bull HG, Calaycay JR, Chapman KT, Howard AD, Kostura MJ, Miller DK, Molineaux SM, Weidner JR, Aunins J, et al. A novel heterodimeric cysteine protease is required for interleukin-1β processing in monocytes. Nature 1992;356:768-774.
51. Yuan J, Shaham S, Ledoux S, Ellis HM, Horvitz HR. The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1β- converting enzyme. Cell 1993;75:641-652.